Literature DB >> 22826624

Microbial profile and antibiotic sensitivity pattern in bile cultures from endoscopic retrograde cholangiography patients.

Muhsin Kaya1, Remzi Beştaş, Fatma Bacalan, Ferhat Bacaksız, Esma Gülsun Arslan, Mehmet Ali Kaplan.   

Abstract

AIM: To identify the frequency of bacterial growth, the most commonly grown bacteria and their antibiotic susceptibility, and risk factors for bacterial colonization in bile collected from patients with different biliary diseases.
METHODS: This prospective study was conducted between April 2010 and August 2011. Patients with various biliary disorders were included. Bile was aspirated by placing a single-use, 5F, standard sphincterotome catheter into the bile duct before the injection of contrast agent during endoscopic retrograde cholangiopancreaticography (ERCP). Bile specimens were transported to the microbiology laboratory in blood culture bottles within an anaerobic transport system. Bacteria were cultured and identified according to the standard protocol used in our clinical microbiology laboratory. The susceptibilities of the organisms recovered were identified using antimicrobial disks, chosen according to the initial gram stain of the positive cultures.
RESULTS: Ninety-one patients (27% male, mean age 53.7 ± 17.5 years, range: 17-86 years) were included in the study. The main indication for ERCP was benign biliary disease in 79 patients and malignant disease in 12 patients. The bile culture was positive for bacterial growth in 46 out of 91 (50.5%) patients. The most frequently encountered organisms were Gram-negative bacteria including Escherichia coli (28.2%), Pseudomonas (17.3%) and Stenotrophomonas maltophilia (15.2%). There were no significant differences between patients with malignant and benign disease (58% vs 49%, P = 0.474), patients with acute cholangitis and without acute cholangitis (52.9% vs 50%, P = 0.827), patients who were empirically administered antibiotics before intervention and not administered (51.4% vs 60.7%, P = 0.384), with regard to the bacteriobilia. We observed a large covering spectrum or low resistance to meropenem, amikacin and imipenem.
CONCLUSION: We did not find a significant risk factor for bacteriobilia in patients with biliary obstruction. A bile sample for microbiological analysis may become a valuable diagnostic tool as it leads to more accurate selection of antibiotics for the treatment of cholangitis.

Entities:  

Keywords:  Bacteriobilia; Bile culture; Cholangitis; Endoscopic retrograde cholangiopancreaticography

Mesh:

Substances:

Year:  2012        PMID: 22826624      PMCID: PMC3400861          DOI: 10.3748/wjg.v18.i27.3585

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  24 in total

1.  Endoscopic biliary drainage for severe acute cholangitis.

Authors:  E C Lai; F P Mok; E S Tan; C M Lo; S T Fan; K T You; J Wong
Journal:  N Engl J Med       Date:  1992-06-11       Impact factor: 91.245

2.  Microbiology and antibiotic susceptibility of organisms in bile cultures from patients with and without cholangitis at an Asian academic medical center.

Authors:  Vincent Bryan D G Salvador; Maria Cristina H Lozada; Rafael J Consunji
Journal:  Surg Infect (Larchmt)       Date:  2011-02-24       Impact factor: 2.150

3.  Bacteriology of the gallbladder bile in normal subjects.

Authors:  A Csendes; M Fernandez; P Uribe
Journal:  Am J Surg       Date:  1975-06       Impact factor: 2.565

4.  Antibiotics in infections of the biliary tract.

Authors:  E L Muller; H A Pitt; J E Thompson; J E Doty; L L Mann; B Manchester
Journal:  Surg Gynecol Obstet       Date:  1987-10

Review 5.  Acute (ascending) cholangitis.

Authors:  L H Hanau; N H Steigbigel
Journal:  Infect Dis Clin North Am       Date:  2000-09       Impact factor: 5.982

6.  Bacteriological study of choledochal bile in patients with common bile duct stones, with or without acute suppurative cholangitis.

Authors:  F Maluenda; A Csendes; P Burdiles; J Diaz
Journal:  Hepatogastroenterology       Date:  1989-06

7.  Urgent endoscopic drainage for acute suppurative cholangitis.

Authors:  J W Leung; S C Chung; J J Sung; V P Banez; A K Li
Journal:  Lancet       Date:  1989-06-10       Impact factor: 79.321

8.  Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis.

Authors:  Rungsun Rerknimitr; Evan L Fogel; Cem Kalayci; Edward Esber; Glen A Lehman; Stuart Sherman
Journal:  Gastrointest Endosc       Date:  2002-12       Impact factor: 9.427

9.  Bacteriology and antimicrobial susceptibility in biliary tract disease: an audit of 10-year's experience.

Authors:  Wen-Tsan Chang; King-Teh Lee; Sen-Ren Wang; Shin-Chang Chuang; Kung-Kai Kuo; Jong-Shyone Chen; Pai-Ching Sheen
Journal:  Kaohsiung J Med Sci       Date:  2002-05       Impact factor: 2.744

10.  Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and gentamicin therapy for patients with cholangitis.

Authors:  W B Gerecht; N K Henry; W W Hoffman; S M Muller; N F LaRusso; J E Rosenblatt; W R Wilson
Journal:  Arch Intern Med       Date:  1989-06
View more
  11 in total

1.  Prospective observational multicenter study to define a diagnostic algorithm for biliary candidiasis.

Authors:  Philipp Lenz; Franziska Eckelskemper; Thomas Erichsen; Tim Lankisch; Alexander Dechêne; Gabriele Lubritz; Frank Lenze; Torsten Beyna; Hansjörg Ullerich; Andre Schmedt; Dirk Domagk
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

2.  Risk factors of organ failure in cholangitis with bacteriobilia.

Authors:  Jae Min Lee; Sang Hyub Lee; Kwang Hyun Chung; Jin Myung Park; Ban Seok Lee; Woo Hyun Paik; Joo Kyung Park; Ji Kon Ryu; Yong-Tae Kim
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

3.  Antibiotic Prophylaxis Prior to Elective ERCP Does Not Alter Cholangitis Rates or Shorten Hospital Stay: Results of an Observational Prospective Study of 138 Consecutive ERCPS.

Authors:  Theodor Alexandru Voiosu; Andreea Bengus; Andrei Haidar; Mihai Rimbas; Alina Zlate; Paul Balanescu; Andrei Voiosu; Radu Voiosu; Bogdan Mateescu
Journal:  Maedica (Buchar)       Date:  2014-12

4.  Microbial Profiles and Risk Factors of Preexisting Biliary Infection in Patients with Therapeutic Endoscopy.

Authors:  Hua-Qiang Ruan; Guo-Lin Liao; Peng Peng; Shi-Quan Liu; Chang-Liang Wu; Jian-Fu Qin; Zhi-Hai Liang; Guo-Du Tang; Meng-Bin Qin; Jie-An Huang
Journal:  Gastroenterol Res Pract       Date:  2019-05-05       Impact factor: 2.260

5.  Clinical and microbiological characteristics of patients with biliary disease.

Authors:  Xue-Xiang Gu; Meng-Pei Zhang; Yan-Feng Zhao; Guang-Ming Huang
Journal:  World J Gastroenterol       Date:  2020-04-14       Impact factor: 5.742

6.  Biliary infection; distribution of species and antibiogram study.

Authors:  Shima Shafagh; Seyed Hamed Rohani; Abbas Hajian
Journal:  Ann Med Surg (Lond)       Date:  2021-09-07

7.  Bacterial profile and antimicrobial susceptibility patterns in cancer patients.

Authors:  Minichil Worku; Gizeaddis Belay; Abiye Tigabu
Journal:  PLoS One       Date:  2022-04-15       Impact factor: 3.752

8.  Immune dysfunction in patients with obstructive jaundice before and after endoscopic retrograde cholangiopancreatography.

Authors:  Abeed H Chowdhury; Miguel Camara; Luisa Martinez-Pomares; Abed M Zaitoun; Oleg Eremin; Guruprasad P Aithal; Dileep N Lobo
Journal:  Clin Sci (Lond)       Date:  2016-06-01       Impact factor: 6.124

9.  Bacterobilia in pancreatic surgery-conclusions for perioperative antibiotic prophylaxis.

Authors:  Colin Markus Krüger; Ulrich Adam; Thomas Adam; Axel Kramer; Claus D Heidecke; Frank Makowiec; Hartwig Riediger
Journal:  World J Gastroenterol       Date:  2019-11-07       Impact factor: 5.742

10.  Helicobacter pylori is not a contributing factor in gallbladder polyps or gallstones: a case-control matching study of Chinese individuals.

Authors:  Jinshun Zhang; Ying Zhang; Yahong Chen; Weiling Chen; Hongfang Xu; Wei Sun
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.